Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Chief Operations Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,226 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 24,000 · Balance 94,226 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 71,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 71,000 · Balance 71,000 F2: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030.
F2: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 71,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000031 · wk-form4_1767734302.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 16:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000031 · wk-form4_1767734302.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,226 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 16:03 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001453687-26-000002 · wk-form4_1767387807.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,369 Underlying: Common Stock · 7,500 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger. F1 · derivative.exercise_date: These options are currently fully vested and exercisable. Read SEC document |
| December 30, 2025 Filed Jan 2, 2026 16:03 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 7,500 | $3.30 | $24,750.00 |
DisclosureSEC source: 0001453687-26-000002 · wk-form4_1767387807.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 16:02 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001453687-25-000130 · wk-form4_1764709364.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,869 Underlying: Common Stock · 7,500 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger. F1 · derivative.exercise_date: These options are currently fully vested and exercisable. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 16:02 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 7,500 | $3.30 | $24,750.00 |
DisclosureSEC source: 0001453687-25-000130 · wk-form4_1764709364.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2025 Filed May 14, 2025 16:15 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001453687-25-000089 · wk-form4_1747253745.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,369 Underlying: Common Stock · 7,500 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger. F1 · derivative.exercise_date: These options are currently fully vested and exercisable. Read SEC document |
| May 12, 2025 Filed May 14, 2025 16:15 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 7,500 | $3.30 | $24,750.00 |
DisclosureSEC source: 0001453687-25-000089 · wk-form4_1747253745.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 16:35 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001453687-25-000068 · wk-form4_1744835744.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,869 Underlying: Common Stock · 7,500 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On November 13, 2023, the issuer acquired the Delaware corporation which was then-known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the issuer's common stock in connection with the merger. F1 · derivative.exercise_date: These options are currently fully vested and exercisable. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 16:35 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 7,500 | $3.30 | $24,750.00 |
DisclosureSEC source: 0001453687-25-000068 · wk-form4_1744835744.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 20:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 906 | $16.83 | $15,249.97 |
DisclosureSEC source: 0001453687-25-000037 · wk-form4_1736298303.xml · nonDerivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,226 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 20:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 891 | $16.72 | $14,899.21 |
DisclosureSEC source: 0001453687-25-000037 · wk-form4_1736298303.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,132 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:21 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 47,400 | $0.00 Strike: $16.93 | $0.00 |
DisclosureSEC source: 0001453687-25-000026 · wk-form4_1736198457.xml · derivative · entry 2 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,400 Underlying: Common Stock · 47,400 shares Expires 2035-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 16:21 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 16,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000026 · wk-form4_1736198457.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · Chief Operations Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,023 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 16:11 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,650 | Not disclosed Strike: $3.30 | Not disclosed |
DisclosureSEC source: 0001453687-24-000149 · wk-form4_1735593112.xml · derivative · entry 2 English Emily · CIK 0002019791 · SVP, Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,369 Underlying: Common Stock · 7,650 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Common Stock in connection with the merger. F1 · derivative.exercise_date: These options are currently exercisable for an additional 35,114 shares of Common Stock and become exercisable for a further 14,255 shares of Common Stock on March 22, 2025. Read SEC document |
| December 26, 2024 Filed Dec 30, 2024 16:11 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 7,650 | $3.30 | $25,245.00 |
DisclosureSEC source: 0001453687-24-000149 · wk-form4_1735593112.xml · nonDerivative · entry 1 English Emily · CIK 0002019791 · SVP, Head of Manufacturing 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.